LMRI Lumexa Imaging Holdings, Inc.
Services-Medical Laboratories · Nasdaq · SEC CIK 2071288 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA—
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets65.4%
Debt / equity1.32x
Current ratio1.52x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $271.97M | $264.16M | $252.54M | $258.94M | $251.40M | $245.00M |
| SG&A expense | $30.02M | $24.40M | $20.34M | $17.08M | $18.69M | $17.49M |
| Operating income | $28.11M | $23.04M | $19.41M | $30.34M | $27.68M | $25.54M |
| Interest expense | $15.67M | $16.22M | $16.33M | $30.58M | $30.10M | $29.85M |
| Pretax income | $11.79M | $5.76M | $3.08M | -$237,000 | -$2.42M | -$4.31M |
| Income tax | $4.61M | $3.02M | $1.36M | $3.26M | $4.81M | $3.38M |
| Net income | $7.18M | $2.75M | $1.72M | -$3.50M | -$7.23M | -$7.69M |
| EBITDA | $38.44M | $33.12M | $29.33M | $39.99M | $36.96M | $34.59M |
| EPS (basic) | 0.07 | 0.03 | 0.02 | -0.05 | -0.10 | -0.11 |
| EPS (diluted) | 0.07 | 0.03 | 0.02 | -0.05 | -0.10 | -0.11 |
| Weighted avg. shares (diluted) | 96.26M | 96.04M | 95.98M | 69.53M | 69.53M | 69.52M |
| Balance sheet | ||||||
| Cash & equivalents | $90.01M | $69.70M | $51.23M | $191,000 | $4.75M | $7.30M |
| Current assets | $278.31M | $256.42M | $221.89M | — | — | — |
| PP&E, net | $158.85M | $156.06M | $150.13M | — | — | — |
| Goodwill | $807.55M | $807.55M | $807.55M | — | — | — |
| Intangibles | $38.58M | $39.72M | $40.24M | — | — | — |
| Total assets | $1.83B | $1.81B | $1.76B | — | — | — |
| Current liabilities | $183.46M | $178.35M | $157.93M | — | — | — |
| Short-term debt | $15.55M | $14.33M | $13.44M | — | — | — |
| Long-term debt | $821.52M | $819.75M | $816.97M | — | — | — |
| Total debt | $837.07M | $834.08M | $830.41M | — | — | — |
| Total liabilities | $1.20B | $1.19B | $1.16B | — | — | — |
| Shareholders' equity | $634.08M | $615.06M | $599.62M | $167.11M | $162.18M | $161.00M |
| Net debt | $747.06M | $764.38M | $779.18M | — | — | — |
| Shares outstanding | 96.06M | 96.07M | 96.08M | — | — | — |
| Cash flow statement | ||||||
| Operating cash flow | $34.81M | $32.80M | $2.93M | $11.86M | $2.07M | -$13.96M |
| Capital expenditure | $14.21M | $9.67M | $5.31M | $13.63M | $4.60M | $1.00M |
| Free cash flow | $20.60M | $23.13M | -$2.38M | -$1.77M | -$2.53M | -$14.96M |
| Investing cash flow | -$14.05M | -$13.64M | -$5.27M | -$13.67M | -$4.17M | -$720,000 |
| Financing cash flow | -$454,000 | -$685,000 | -$5.26M | -$2.75M | -$462,000 | -$4.15M |
| Depreciation & amortization | $10.33M | $10.08M | $9.92M | $9.65M | $9.28M | $9.05M |
| Stock-based compensation | $12.34M | $12.74M | $12.27M | $8.31M | $8.35M | $6.37M |
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.